Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
ALC.SW

Price
61.90
Stock movement down
-0.50 (-0.79%)
Company name
Alcon AG
Exchange
(SW
,
Currency
CHF
)
Sector
Healthcare >
Medical Instruments & Supplies
Market cap
30.49B
Ent value
38.48B
Price/Sales
2.93
Price/Book
1.38
Div yield
-
Div growth
-
Growth years
-
FCF payout
10.03%
Trailing P/E
31.06
Forward P/E
14.30
PEG
-
EPS growth
-
1 year return (CAGR)
-23.84%
3 year return (CAGR)
-0.52%
5 year return (CAGR)
-0.25%
10 year return (CAGR)
-
Last updated: 2026-03-11

DIVIDENDS

ALC.SW does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E31.06
Price to OCF13.56
Price to FCF17.82
Price to EBITDA22.42
EV to EBITDA28.29

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.93
Price to Book1.38
EV to Sales3.69

FINANCIALS

Per share

Loading...
Per share data
Current share count487.43M
EPS (TTM)1.99
FCF per share (TTM)3.48

Income statement

Loading...
Income statement data
Revenue (TTM)10.42B
Gross profit (TTM)5.76B
Operating income (TTM)1.36B
Net income (TTM)981.77M
EPS (TTM)1.99
EPS (1y forward)4.38

Margins

Loading...
Margins data
Gross margin (TTM)55.24%
Operating margin (TTM)13.07%
Profit margin (TTM)9.42%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash1.53B
Net receivables2.17B
Total current assets6.44B
Goodwill9.25B
Intangible assets9.00B
Property, plant and equipment0.00
Total assets31.53B
Accounts payable925.39M
Short/Current long term debt5.67B
Total current liabilities3.05B
Total liabilities9.51B
Shareholder's equity22.02B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)2.25B
Capital expenditures (TTM)537.99M
Free cash flow (TTM)1.71B
Dividends paid (TTM)171.56M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity4.46%
Return on Assets3.11%
Return on Invested Capital4.33%
Cash Return on Invested Capital7.55%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open63.02
Daily high63.52
Daily low62.18
Daily Volume990K
All-time high84.68
1y analyst estimate78.52
Beta0.70
EPS (TTM)1.99
Dividend per share0.00
Ex-div date13 May 2025
Next earnings date24 Feb 2026

Downside potential

Loading...
Downside potential data
ALC.SWS&P500
Current price drop from All-time high-26.90%-1.82%
Highest price drop-38.19%-56.47%
Date of highest drop23 Mar 20209 Mar 2009
Avg drop from high-11.85%-10.84%
Avg time to new high40 days12 days
Max time to new high600 days1805 days
COMPANY DETAILS
ALC.SW (Alcon AG) company logo
Marketcap
30.49B
Marketcap category
Large-cap
Description
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Employees
25942
Investor relations
-
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.
March 10, 2026
Is everything old new again? We had a financial crisis in 2008, and while market moods are better than that these days, some analysts are starting to see some disturbing parallels. That’s the view of ...
March 7, 2026
Rigetti beats earnings estimates in Q4 with a narrower loss, but revenue declines year over year and margins contract amid higher operating expenses.
March 5, 2026
Earnings, Dividend Proposal, and Board Change Put Alcon in Focus Alcon (SWX:ALC) is back on investors’ radar after its fourth quarter and full year 2025 results, a proposed 2025 dividend, and an upcom...
March 5, 2026
Moby summary of STAAR Surgical Company's Q4 2025 earnings call
March 4, 2026
STAAR Surgical (NASDAQ:STAA) executives emphasized a return to execution in fiscal 2026 after what they described as a disruptive and transitional 2025, highlighting progress in China channel inventor...
March 4, 2026
Here is how Alcon (ALC) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
March 2, 2026
GENEVA, March 02, 2026--Alcon Surpasses 175 Million IOLs Implanted Globally
March 2, 2026
CLOV Q4 loss matches estimates. Revenues jump 45%. The 2026 outlook calls for up to 49% growth and potential GAAP profitability.
February 27, 2026
XRAY climbs nearly 8% pre-market as it unveils a $120M restructuring plan, even after Q4 earnings miss and softer 2026 outlook.
February 27, 2026
Next page